戈利木单抗真实世界两年药物留存率及临床结局预测因素
该前瞻性观察队列纳入416例起始戈利木单抗治疗的RA、SpA和PsA患者,其中171例生物制剂初治、245例既往生物制剂应答不足。总体2年药物留存率为70.2%,不同疾病或生物制剂治疗线间停药风险无差异;女性、单药治疗及RA 3个月未达良好EULAR应答是停药预测因素。
要点
- 总体2年戈利木单抗留存率为70.2%,RA、SpA、PsA及不同治疗线间停药风险无差异。
- 女性是停药最强预测因素(HR=1.95),单药治疗与更高中断风险相关(HR=1.67)。
- RA患者3个月未达良好EULAR应答是唯一停药预测因素(HR=3.03)。
核心结论
- 戈利木单抗在真实世界RA、SpA和PsA患者中具有较高2年药物留存率。
- SpA男性伴关节外表现、PsA联合DMARDs治疗及RA早期临床应答者最可能持续使用戈利木单抗超过2年。
研究设计与样本
- 前瞻性观察性纵向非干预研究,纳入416例起始戈利木单抗治疗的RA、SpA和PsA患者。
- 171例为生物制剂初治,245例为既往生物制剂应答不足;RA 88例、SpA 147例、PsA 181例。
- 终点为2年戈利木单抗留存率及治疗中断预测因素,采用Kaplan-Meier和Cox模型分析。
主要发现
- 总体2年药物留存率为70.2%,不同疾病或生物制剂治疗线间停药风险无差异。
- 女性是戈利木单抗停药最强预测因素(HR=1.95)。
- 戈利木单抗单药治疗与更高治疗中断风险相关(HR=1.67)。
- SpA中停药预测因素为女性(HR=4.19)和无关节外表现(HR=4.60)。
- PsA中病程与治疗中断负相关(HR=0.93),单药治疗正相关(HR=2.21);RA中3个月未达良好EULAR应答是唯一停药预测因素(HR=3.03)。
关键数值与推荐
- 总体2年戈利木单抗留存率为70.2%。
- 女性停药HR=1.95;单药治疗中断HR=1.67;RA 3个月未达良好EULAR应答HR=3.03。
- SpA女性停药HR=4.19,无关节外表现HR=4.60;PsA病程HR=0.93,单药治疗HR=2.21。
临床怎么用
- 真实世界中戈利木单抗2年留存率较高,可作为RA、SpA和PsA的持续治疗选择。
- 女性、单药治疗及RA早期未达EULAR良好应答者需关注停药风险,考虑联合DMARDs或强化评估。
- SpA男性伴关节外表现及PsA联合DMARDs治疗者持续用药概率更高。
局限性
- 原文摘要未报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To assess the drug survival of golimumab, and predictors thereof, in patients affected with rheumatoid arthritis (RA), spondyloarthritis (SpA), and psoriatic arthritis (PsA) in a prospective observational cohort. METHODS: This is a non-interventional, longitudinal study on RA, SpA, and PsA patients starting treatment with golimumab. Endpoints were the 2 years persistence rate of golimumab and predictors of therapy discontinuation. Drug retention was analyzed using Kaplan-Meier and Cox models. Hazard ratios (HR) of golimumab discontinuation were estimated by Cox-regression hazard models. RESULTS: Of 416 patients starting golimumab, 171 biologic-naïve and 245 inadequate responders to prior biologic drugs, 88 had RA, 147 SpA, and 181 PsA. Global 2 years drug retention was 70.2%, with no different hazard of discontinuation among diseases or line of biologic treatment. The strongest predictor of golimumab discontinuation was female gender (HR = 1.95). Golimumab monotherapy was associated with higher risk drug interruption (HR = 1.67). Within SpA, predictors of golimumab discontinuation were female sex (HR = 4.19), and absence of extra-articular manifestations (HR = 4.60). In PsA, duration of disease was negatively associated to drug interruption (HR = 0.93), whereas golimumab monotherapy was positively (HR = 2.21) associated. Interestingly, failing to achieve a good EULAR response at 3 months was the only predictor of golimumab discontinuation for RA patients (HR = 3.03). CONCLUSIONS: This study provided evidence that golimumab has high retention rate in real-life settings. SpA male patients with extra-articular manifestations, PsA patients on co-therapy with DMARDs, and RA patients attaining an early clinical response had the highest probability to continue golimumab over 2 years.
引用
- Iannone F, Santo L, Anelli MG, et al. Golimumab in real-life settings: 2 Years drug survival and predictors of clinical outcomes in rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis. Semin Arthritis Rheum. 2017. PMID: 28216195. doi:10.1016/j.semarthrit.2017.01.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。